Targeted Cascade Therapy with Multifunctional Nanovesicles Engineered from Synergistic Antibacterial Agents for Precision Treatment of Multidrug-Resistant Infections and Biofilms.
{"title":"Targeted Cascade Therapy with Multifunctional Nanovesicles Engineered from Synergistic Antibacterial Agents for Precision Treatment of Multidrug-Resistant Infections and Biofilms.","authors":"Yiyu Gong,Min Lin,Dongze Li,Rui Yao,Guojing Zhang,Jing Sun,Xuesi Chen","doi":"10.1002/adma.202511037","DOIUrl":null,"url":null,"abstract":"Multidrug-resistant (MDR) Staphylococcus aureus (S. aureus), classified as a high-priority tier II pathogen, poses a glowing threat to global health. Single-mode antibacterial approaches often fall short of achieving optimal effects, necessitating the development of combination therapies. To address these challenges, pH-responsive antibacterial nanovesicles, termed DAClLy, are developed by integrating targeting ligand and multiple antimicrobial agents with complementary modes of action to target MDR bacteria with enhanced efficacy while minimizing adverse effects. DAClLy are engineered through the complexation of sulfonium-ion-bearing antibacterial polypeptoids, and primary amine-containing polypeptoids modified with 2,3-dimethyl maleic anhydride, encapsulating lysostaphin, a bacteriolytic enzyme. Upon reaching the acidic microenvironment of bacterial infections, the DAClLy vesicles disassemble, releasing their antimicrobial components. The released lysostaphin degrades bacterial cell walls, while the polypeptoids synergistically disrupt bacterial membranes, resulting in a multi-action bactericidal effect. This synergistic mechanism demonstrates remarkable efficacy against MDR S. aureus, including its resilient biofilm formations. In vivo studies have shown that the DAClLy vesicles exhibit potent antibacterial activity against MDR S. aureus-induced skin and lung infections. The nanovesicles effectively penetrate the lung mucus barrier, addressing both surface-level and deep-tissue infections. By integrating multiple strategies, DAClLy offers a promising therapeutic strategy to combat MDR pathogens across diverse tissue contexts.","PeriodicalId":114,"journal":{"name":"Advanced Materials","volume":"35 1","pages":"e11037"},"PeriodicalIF":26.8000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Materials","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1002/adma.202511037","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Multidrug-resistant (MDR) Staphylococcus aureus (S. aureus), classified as a high-priority tier II pathogen, poses a glowing threat to global health. Single-mode antibacterial approaches often fall short of achieving optimal effects, necessitating the development of combination therapies. To address these challenges, pH-responsive antibacterial nanovesicles, termed DAClLy, are developed by integrating targeting ligand and multiple antimicrobial agents with complementary modes of action to target MDR bacteria with enhanced efficacy while minimizing adverse effects. DAClLy are engineered through the complexation of sulfonium-ion-bearing antibacterial polypeptoids, and primary amine-containing polypeptoids modified with 2,3-dimethyl maleic anhydride, encapsulating lysostaphin, a bacteriolytic enzyme. Upon reaching the acidic microenvironment of bacterial infections, the DAClLy vesicles disassemble, releasing their antimicrobial components. The released lysostaphin degrades bacterial cell walls, while the polypeptoids synergistically disrupt bacterial membranes, resulting in a multi-action bactericidal effect. This synergistic mechanism demonstrates remarkable efficacy against MDR S. aureus, including its resilient biofilm formations. In vivo studies have shown that the DAClLy vesicles exhibit potent antibacterial activity against MDR S. aureus-induced skin and lung infections. The nanovesicles effectively penetrate the lung mucus barrier, addressing both surface-level and deep-tissue infections. By integrating multiple strategies, DAClLy offers a promising therapeutic strategy to combat MDR pathogens across diverse tissue contexts.
期刊介绍:
Advanced Materials, one of the world's most prestigious journals and the foundation of the Advanced portfolio, is the home of choice for best-in-class materials science for more than 30 years. Following this fast-growing and interdisciplinary field, we are considering and publishing the most important discoveries on any and all materials from materials scientists, chemists, physicists, engineers as well as health and life scientists and bringing you the latest results and trends in modern materials-related research every week.